Following the company’s third quarter results, National Bank Financial analyst Richard Tse has raised his price target on CGI (CGI Stock Quote, Chart, News, Analysts, Financials TSX:GIB.A).
On July 31, CGI reported its Q3, 2024 results. The company posted Adjusted EBIT of $60.28-million on revenue of $3.67-billion, a topline that was up 1.3% over the same period a year prior.
The analyst summarized the quarter.
“CGI reported essentially in-line FQ3 (CQ2) results this morning. We estimate organic growth in the quarter was essentially flat to slightly negative in constant currency — that’s positive against what’s been a challenging backdrop for IT Services. More importantly, the leading indicator of bookings (and book-to-bill) pointed to a positive outlook. In particular, we’d note Managed Services (recurring revenue) book-to-bill came in at 1.39x.”
In a research update to clients July 31, Tse maintained his “Outperform” rating on CGI and raised his price target from $175.00 to $185.00, implying a return of 17.5% at the time of publication.
The analyst thinks CGI will post EBITDA of $2.97-billion on revenue of $14.6-billion in fiscal 2024. He expects those numbers will improve to EBITDA of $3.15-billion on revenue of $15.3-billion in fiscal 2025.
“Bottom line, despite what has been a soft (macro) enterprise spend backdrop, CGI has been able to drive operating leverage, a reflection of its operating prowess that should benefit from scaling revenue via organic and acquisition initiatives,” Tse added.
RBC Dominion Securities Drew McReynolds likes what he currently sees from Stingray Group (Stingray Group Stock Quote, Chart, News, Analysts,… [Read More]
CGI is doubling down on growth through acquisition, and National Bank Financial is betting on the strategy paying off, maintaining… [Read More]
Even with a cautious market, Constellation Software’s (Constellation Software Stock Quote, Chart, News, Analysts, Financials TSX:CSU) steady deal flow and… [Read More]
New clinical data from Medicenna Therapeutics (Medicenna Therapeutics Stock Quote, Chart, News, Analysts, Financials TSXV:MDNA) is strengthening confidence in its… [Read More]
Roth Capital sees a big upside for GeoVax after the company released promising new vaccine data. GeoVax Labs (GeoVax Labs… [Read More]
The tailwinds have long subsided and the headwinds are coming. That's the take from Citi analyst Paul Lejuez when it… [Read More]